SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, for instance, have been proven to decrease cardiovascular incidents, reduce hospitalizations due to heart failure, and enhance kidney health in people with type 2 diabetes mellitus (T2DM) [7].